90 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
31 May 24
Regulation FD Disclosure
4:21pm
total). The primary endpoint of the trial is progression free survival (PFS) by blinded independent central review (BICR), with secondary endpoints
8-K
EX-10.2
IMCR
Immunocore Holdings plc
28 May 24
Entry into a Material Definitive Agreement
4:17pm
expenses, (iv) all fees and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including … to underwriters in an underwritten public offering, addressed to the underwriters, and (ii) a letter or letters from the independent certified public
8-K
IMCR
Immunocore Holdings plc
23 May 24
Submission of Matters to a Vote of Security Holders
4:50pm
officers.
Resolution 5: To ratify the appointment of Deloitte LLP as the Company’s U.S. independent registered public accounting firm for the year ending
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
experimental arms (90 patients randomized total). The primary endpoint of the trial is progression free survival (PFS) by blinded independent central review
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
the appointment of Deloitte LLP, a limited liability partnership organized under the laws of England, as our U.S. independent registered public accounting … parties and/or independent election candidates not exceeding £50,000 in total;
make political donations to political organizations other than political
8-K
EX-5.1
vh3syg2e2f
5 Apr 24
Other Events
4:35pm
424B7
hv2mhtkw1is5uxytp3h
5 Apr 24
Prospectus with selling stockholder info
4:34pm
PRE 14A
71pl rnr407owaeu
2 Apr 24
Preliminary proxy
4:45pm
S-8
EX-23.2
6m4r78
20 Mar 24
Registration of securities for employees
8:55pm
S-8
EX-23.1
4rnwmdl tof5zuy4ip
20 Mar 24
Registration of securities for employees
8:55pm
S-8
hwkdbon yn2
20 Mar 24
Registration of securities for employees
8:55pm
S-3ASR
EX-23.2
zid40 ejsmip7u1ar3do
20 Mar 24
Automatic shelf registration
8:51pm
S-3ASR
9yn615x9vmml1g vjhj
20 Mar 24
Automatic shelf registration
8:51pm
S-3ASR
EX-5.2
lmi9znm2f7a0
20 Mar 24
Automatic shelf registration
8:51pm
S-3ASR
EX-23.1
qof2ntmc
20 Mar 24
Automatic shelf registration
8:51pm
S-3ASR
EX-5.1
72ya9lvo
20 Mar 24
Automatic shelf registration
8:51pm
8-K
EX-99.1
rq1mh1aa6xf 8c05v
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
8-K
EX-99.2
eumnr6h31wg
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
EX-23.2
zv9g84t i3
28 Feb 24
Annual report
7:33am
10-K
EX-23.1
y0b1tupr 71
28 Feb 24
Annual report
7:33am